Samsung Biologics, Kurma Partners Strike Development and Manufacturing Deal

Published on: 

Collaboration to focus on biologics of Kurma’s portfolio companies.

Samsung Biologics, a contract development and manufacturing organization (CDMO), and Kurma Partners, a healthcare and biotechnology venture capital firm, announced a partnership focused on the development and manufacturing of biologics for Kurma Partners' portfolio companies. Under terms of the deal, Samsung Biologics will provide customizable chemistry, manufacturing, and control (CMC) development services for Kurma Partners' portfolio companies to streamline the gene to investigational new drug (IND) process, de-risk uncertainties in CMC, and accelerate the lead candidate selection through entry into first-in-human studies with seamless transitions along further clinical development.


"As we look to further expand our business opportunities globally, we are pleased to collaborate with Kurma Partners to support the growth of pioneering biotech companies," said John Rim, President, CEO, Samsung Biologics. "With our in-depth knowledge on effective scale-up strategy and a diverse portfolio of proprietary platform technologies, we are looking forward to providing robust CMC solutions to reduce uncertainties, ensure regulatory compliance, and ultimately maximize manufacturing efficiency for our clients."

Reference: Samsung Biologics and Kurma Partners announce strategic partnership for development and manufacturing of biologics for Kurma's portfolio companies. PR Newswire. October 23, 2023. Accessed October 24, 2023.